Arecor Therapeutics PLC (AIM:AREC), the AIM-listed diabetes biotech, will present at the Oppenheimer 36th Annual Healthcare MedTech and Services Conference on 16 March.
Chief executive Sarah Howell will present on AT278, the company's lead insulin programme, at 9.20am EDT.
Howell, chief scientific officer Jan Jezek and chief development officer David Gerring will also attend the Advanced Technologies and Treatments for Diabetes conference in Barcelona from 11-14 March.